Article
Two naturally occurring mutations in the type 1 melanin-concentrating hormone receptor abolish agonist-induced signaling.
The Journal of pharmacology and experimental therapeutics - 1 Dec 2010
Goldstein Carmit, Schroeder Jonathan C, Fortin Jean-Philippe, Goss Jennifer M, Schaus Scott E, Beinborn Martin, Kopin Alan S
Abstract excerpt
The melanin-concentrating hormone (MCH) receptor type 1 (MCHR1) is a seven-transmembrane domain protein that modulates orexigenic activity of MCH, the corresponding endogenous peptide agonist. MCH antagonists are being explored as a potential treatment for obesity. In the current study, we examined the pharmacological impact of 11 naturally occurring mutations in the human MCHR1. Wild-type and mutant receptors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
